Exabis Library
Welcome to the e-CCO Library!
P687: Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P688 Effect of golimumab induction therapy on histologic disease profile in patients with moderate to severe ulcerative colitis: Results from the randomised, placebo-controlled Phase 3 PURSUIT-SC trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P688: Association of Akkermansia muciniphila with a healthy gut microbiome
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P688: Crohn's disease patients with a concordant family history are diagnosed earlier and are at increased risk for complicated disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P688: Demographic, clinical, and therapeutic characteristics of a cohort of 238 patients with ulcerative colitis from two medical centres from Uruguay
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P688: Patient preferences in medication to treat Ulcerative Colitis: a discrete choice experiment
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P688: Sex difference in inflammatory bowel disease patients regarding depression: a nationwide population based study in Korea
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P688: Ustekinumab in resistant Crohn’s disease: 1-year UK IBD tertiary referral centre ‘real-world’ experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P689 Patient-reported outcomes (PRO-2) and intestinal ultrasound in ulcerative colitis patients: subanalysis of the TRUST&UC study cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P689: Aeromonas infection and Inflammatory Bowel Disease: a single tertiary center analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P689: Biologics utilization in children with inflammatory bowel diseases is higher and earlier than in adults: a report from the epi-IIRN group
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P689: Multicenter, cross-sectional, observational study on Epstein–Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P689: Predictive transcriptional signatures associated to vedolizumab therapy response in patients with ulcerative colitis.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P689: The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P689: UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P690: Ambient air quality does not affect disease course in inflammatory bowel disease – a population based risk factor analysis using geographic information systems
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P690: Changes of intestinal microbiota in patients with inflammatory bowel diseases
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P690: Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P690: Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM